Skip to main content
Clinical Trials/CTRI/2023/05/052159
CTRI/2023/05/052159Not yet recruitingPhase 3

A Randomized, Open Label, Comparative, Clinical Study To Evaluate The Efficacy And Safety of Trumove Tablet In Patients With Diabetic Neuropathic Pain

Tirupati Pharma, India0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 3. Patients who are able to understand written and/or verbal instructions and are ready to comply with all study requirements with a willingness to participate and give written informed consent
  • voluntarily.
  • Patients who had been diagnosed with mild to moderate Diabetic Neuropathic Pain.

Exclusion Criteria

  • 1. Women of child bearing potential who are either unwilling or
  • unable to use an acceptable method of birth control to avoid
  • pregnancy during the study period.
  • 2. Subjects with Severe co morbid disease conditions like Heart
  • failure, Renal Failure or Liver failure.
  • 3. Subject with history of uncontrolled diabetes (HbA1c > 10)
  • 4. Known allergy to compounds of investigational product.
  • 5. Participation in an investigational drug trial in the30 days
  • prior to the screeningvisit.
  • 6. Patients of vulnerable group (children, lactating mother,
  • elderly >80 years,handicapped, seriously ill, mentally
  • challenged).
  • 7. History of drug or alcohol abuse during the last 6 months.

Investigators

Sponsor
Tirupati Pharma, India

Similar Trials